Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: It will be interesting to see how PTSC can impact TPL

Wasn't your proposal about Preferred Stock?

BASES FOR EXCLUSION

    We believe that the Proposal may properly be excluded from the 2008 Proxy Materials pursuant

    to:

    1. Rule 14a-8(i)(2), because implementation of the Proposal would cause the

    Company to violate Delaware law;

  1. Rule l4a-8(i)(1), because the Proposal is not a proper subject for stockholder
  2. action under Delaware law;
  3. Rule l4a-8(i)(7), because the Proposal deals with a matter relating to the
    1. Company's ordinary business operations; and

    4. Rule l4a-8(i)(3), because the Proposal is vague and indefinite.

    THE PROPOSAL

    The Proposal resolves that "the Stockholders of the Company hereby direct the Board to take all

    actions necessary to eliminate the issuance of Preferred Stock without the prior approval of

    Stockholders holding a majority of the outstanding Common Stock." (emphasis added). A copy of the Proposal is enclosed with this letter.

    http://www.sec.gov/divisions/corpfin/cf-noaction/14a-8/2008/patriotscientificcorp082108-14a8.pdf

    Still smiling.

    What are your motives?

    .

    .

    .

    Be well

    Share
    New Message
    Please login to post a reply